Antineoplastic Agents

Tamoxifen citrate is a kind of estrogen competitive antagonist, which is a non steroidal anti estrogen drug. It can compete with estrogen in vivo and combine with estrogen receptor of breast cancer cells, so as to inhibit the effect of estrogen on cancer cells, hinder the growth and development of tumor cells, and play an anti-cancer effect. It is commonly used in the treatment of various types of breast cancer. It is especially suitable for women with postmenopausal breast cancer who have estrogen receptor and progesterone receptor positive and low level of prostate specific antigen.

Letrozole is a new generation of highly selective aromatase inhibitor, which is a synthetic benzyltriazole derivative. By inhibiting aromatase, letrozole can reduce the level of estrogen, so as to eliminate the stimulating effect of estrogen on tumor growth. The in vivo activity is 150-250 times stronger than that of the first generation aromatase inhibitor amlumide. Because of its high selectivity, it does not affect the function of glucocorticoid, mineralocorticoid and thyroid. High dose use has no inhibitory effect on the secretion of adrenal corticosteroids, so it has a high therapeutic index. Preclinical studies have shown that letrozole has no potential toxicity, mutagenic and carcinogenic effects on various systems and target organs of the body, and has less toxic and side effects, good tolerance. Compared with other aromatase inhibitors and anti estrogen drugs, letrozole has stronger anti-tumor effect. It is suitable for the treatment of patients with advanced breast cancer who are not effective in the treatment of estrogen and early treatment of breast cancer.

This product can be used as medicine raw material and anti-tumor drug.

Oxaliplatin, which belongs to platinum derivatives and is clinically used to treat patients with colorectal cancer metastases after failure of fluorouracil treatment, either alone or in combination with fluorouracil, is the third-generation novel platinum based antitumor compound after cisplatin, carboplatin and the only complex platinum based drug with significant activity against colorectal cancer to date. The principle of action is to act on DNA by producing alkylated conjugates, forming intra - and interstrand crosslinks that inhibit DNA synthesis and replication. It also inhibited proliferation in ovarian cancer and melanoma cell lines.

Nilotinib is a new targeted tumor therapeutic drug, which belongs to tyrosine kinase inhibitor. It is used to treat patients with chronic myeloid leukemia (CML) resistant to glipizide (imatinib). Gleevec is the preferred drug developed by Novartis for the treatment of chronic myeloid leukemia (CML). Nilotinib is improved from the molecular structure of imatinib. It has stronger selectivity for bcr-abl kinase activity. Its inhibitory effect on tyrosine kinase is 30 times stronger than imatinib. It can inhibit the kinase activity of BCR-ABL mutant resistant to imatinib. It can also inhibit kit and PDGFR kinase activities.